Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas

Oncogene

Volumn 36, Issue 43, 2017, Pages 6049-6058

  Yan, D ^a   Kowal, J ^b   Akkari, L ^a,b   Schuhmacher, A J ^a   Huse, J T ^c   West, B L ^d   Joyce, J A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d PLEXXIKON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE; DOVITINIB; PLX 3397; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VATALANIB; 5-((5-CHLORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)METHYL)-N-((6-(TRIFLUOROMETHYL)PYRIDIN-3-YL)METHYL)PYRIDIN-2-AMINE; AMINOPYRIDINE DERIVATIVE; BECAPLERMIN; CSF1R PROTEIN, MOUSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; DRUG BLOOD LEVEL; DRUG EFFICACY; GLIOMA; GLIOMA CELL; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; PATHOLOGY; TUMOR CELL LINE;

AMINOPYRIDINES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; MICE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-SIS; PYRROLES; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; TUMOR MICROENVIRONMENT;

EID: 85032475327     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.261     Document Type: Article

References (38)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
3. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26: 756-784.
4. Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017; 31: 326-341.
5. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009; 4: e7752.
6. Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs Curr Top Microbiol Immunol 2012; 355: 135-169.
7. Geng L, Shinohara ET, Kim D, Tan J, Osusky K, Shyr Y et al. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys 2006; 64: 263-271.
8. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12: 4899-4907.
9. Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest 2008; 118: 3109-3122.
10. Paul I, Bhattacharya S, Chatterjee A, Ghosh MK. Current understanding on EGFR and Wnt/beta-Catenin signaling in glioma and their possible crosstalk. Genes Cancer 2013; 4: 427-446.
11. Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer 2011; 10: 128.
12. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488: 522-526.
13. Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C et al. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther 2012; 11: 2183-2192.
14. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014; 4: 80-93.
15. Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep 2016; 17: 2445-2459.
16. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia 2012; 60: 502-514.
17. Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY et al. Immunotherapy advances for glioblastoma. Neuro Oncol 2014; 16: 1441-1458.
18. Kennedy BC, Showers CR, Anderson DE, Anderson L, Canoll P, Bruce JN et al. Tumor-associated macrophages in glioma: friend or foe J Oncol 2013; 2013: 486912.
19. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 antiinflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216: 15-24.
20. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006; 8: 261-279.
21. Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One 2012; 7: e43339.
22. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19: 1264-1272.
23. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1: 54-67.
24. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 2015; 373: 428-437.
25. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
26. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941-2948.
27. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001; 15: 1913-1925.
28. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 2004; 64: 4783-4789.
29. Uhrbom L, Nerio E, Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 2004; 10: 1257-1260.
30. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005; 11: 3633-3641.
31. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-896.
32. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23: 277-286.
33. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015; 27: 462-472.
34. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol 2016; 18: 557-564.
35. Schafer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F et al. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. J Cancer Res Clin Oncol 2016; 142: 1581-1589.
36. Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 2016; 352: aad3018.
37. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
38. Hallett PJ, Collins TL, Standaert DG, Dunah AW. Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. Curr Protoc Neurosci 2008; Chapter 1: Unit 1,16.